Physician profile
Mackenzie Macintyre
NPI 1326323478
$6,122.25
in general payments reported to CMS, 2019-2025
21 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,849 · 2020: $452 · 2021: $775 · 2022: $568 · 2023: $437 · 2024: $769 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,478.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,477.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $2,415.84 | 2019-2022 | |
| Alcon Vision LLC | $678.14 | 2021-2024 | Eysuvis, Hydrus Microstent, Rocklatan |
| Oyster Point Pharma, INC. | $536.22 | 2023-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $314.93 | 2019-2022 | |
| Allergan, INC. | $308.77 | 2019-2022 | |
| Kala Pharmaceuticals, INC. | $302.82 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $258.51 | 2024-2025 | Xdemvy |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $220.04 | 2019-2021 | |
| Aerie Pharmaceuticals, INC. | $148.88 | 2019-2021 | |
| Bausch & Lomb Americas INC. | $147.19 | 2023-2025 | Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $140.14 | 2022 | |
| Shire North American Group INC | $136.14 | 2019 | |
| Biotissue Holdings INC. | $132.85 | 2019-2025 | |
| Carl Zeiss Meditec, INC. | $81.74 | 2020 | |
| Novartis Pharmaceuticals Corporation | $80.68 | 2019-2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $66.50 | 2021 | |
| Harrow Eye, LLC | $49.08 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $37.22 | 2019-2021 | |
| Dompe US, INC. | $35.88 | 2021-2025 | Oxervate |
| Sight Sciences, INC. | $17.09 | 2020 | |
| Coopervision INC. | $13.59 | 2023 | Myday Contact Lens |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mackenzie Macintyre listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.